This clinical trial is focused on studying the effects of a treatment for Calcific Aortic Valve Stenosis, a condition where the heart’s aortic valve becomes narrowed due to calcium buildup, making it harder for the heart to pump blood. The treatment being tested is called pelacarsen, also known by its code name TQJ230. Pelacarsen is an antisense oligonucleotide, which is a type of medication designed to lower levels of a specific protein in the blood called lipoprotein(a). This protein is linked to the progression of the disease.

The purpose of the study is to see if pelacarsen can slow down the worsening of calcific aortic valve stenosis. Participants in the study will receive either pelacarsen or a placebo, which looks like the treatment but does not contain the active medication. The study will last for about 36 months, during which participants will receive regular injections of the treatment or placebo. The effects of the treatment will be monitored through various tests, including echocardiography, which uses sound waves to create images of the heart, and computed tomography (CT), a type of imaging that provides detailed pictures of the heart’s structure.

Throughout the study, changes in the heart’s function and structure will be assessed to determine if pelacarsen is effective in slowing the disease’s progression. Participants will also have their lipoprotein(a) levels checked, and any side effects or health changes will be closely monitored to ensure safety. The study aims to provide valuable information on whether pelacarsen can be a beneficial treatment for people with calcific aortic valve stenosis.